Department of Psychiatry, Wonkwang University School of Medicine, Iksan, Korea.
Clin Psychopharmacol Neurosci. 2013 Dec;11(3):168-9. doi: 10.9758/cpn.2013.11.3.168. Epub 2013 Dec 24.
Clozapine remains the treatment of choice in refractory schizophrenia despite its various requirement to prescribe, such as mandatory blood monitoring program and various metabolic complication. Currently, clozapine is recommended only after two failed adequate antipsychotics trials. We report a case of a successful early clozapine trial in the treatment of first-episode schizophrenia patient, considering poor treatment response and repeated self-injurious behavior. This case highlights the efficacy of an early clozapine trial as a second-line treatment for first-episode schizophrenia in contrast to switching or combination treatment strategy.
氯氮平仍然是难治性精神分裂症的治疗选择，尽管其有各种规定的要求，如强制性的血液监测计划和各种代谢并发症。目前，只有在两种充分的抗精神病药物试验失败后，才建议使用氯氮平。我们报告了一例首例精神分裂症患者早期氯氮平试验成功的病例，考虑到治疗反应不佳和反复的自伤行为。该病例强调了早期氯氮平试验作为二线治疗首发精神分裂症的疗效，与转换或联合治疗策略形成对比。
